PAPER Oh YS, Yoo SW, Lyoo CH, Yoo JY, Yoon H, Ha S, Lee KS, Kim JS
SEARCH RESULTS
19304 RESULTS
PAPER Minakawa EN, Nagai Y
Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases.
Front Neurosci. 2021;15:621996. Epub 2021 Feb 12 PubMed: 33642983PAPER Bèchet NB, Shanbhag NC, Lundgaard I
Glymphatic pathways in the gyrencephalic brain.
J Cereb Blood Flow Metab. 2021 Sep;41(9):2264-2279. Epub 2021 Feb 27 PubMed: 33641515PAPER Wang S, Su G, Zhang X, Song G, Zhang L, Zheng L, Zhao M
Characterization and Exploration of Potential Neuroprotective Peptides in Walnut (Juglans regia) Protein Hydrolysate against Cholinergic System Damage and Oxidative Stress in Scopolamine-Induced Cognitive and Memory Impairment Mice and Zebrafish.
J Agric Food Chem. 2021 Mar 10;69(9):2773-2783. Epub 2021 Mar 1 PubMed: 33645974PAPER Szwedo AA, Pedersen CC, Ushakova A, Forsgren L, Tysnes OB, Counsell CE, Alves G, Lange J, Macleod AD, Maple-Grødem J
Association of SNCA Parkinson's Disease Risk Polymorphisms With Disease Progression in Newly Diagnosed Patients.
Front Neurol. 2020;11:620585. Epub 2021 Feb 10 PubMed: 33643180PAPER Alnefeesi Y, Siegel A, Lui LM, Teopiz KM, Ho RC, Lee Y, Nasri F, Gill H, Lin K, Cao B, Rosenblat JD, McIntyre RS
Impact of SARS-CoV-2 Infection on Cognitive Function: A Systematic Review.
Front Psychiatry. 2020;11:621773. Epub 2021 Feb 10 PubMed: 33643083PAPER Chen L, Dodge HH, Asgari M
Topic-Based Measures of Conversation for Detecting Mild Cognitive Impairment.
Proc Conf Assoc Comput Linguist Meet. 2020 Jul;2020:63-67. PubMed: 33642674PAPER Chang Y, Yao Y, Ma R, Wang Z, Hu J, Wu Y, Jiang X, Li L, Li G
Dl-3-n-Butylphthalide Reduces Cognitive Deficits and Alleviates Neuropathology in P301S Tau Transgenic Mice.
Front Neurosci. 2021;15:620176. Epub 2021 Feb 10 PubMed: 33642981PAPER Zhou X, Fu AK, Ip NY
APOE signaling in neurodegenerative diseases: an integrative approach targeting APOE coding and noncoding variants for disease intervention.
Curr Opin Neurobiol. 2021 Aug;69:58-67. Epub 2021 Feb 26 PubMed: 33647674Randall Schommer
Joliet, United States
PAPER Sciamanna G, Ponterio G, Tassone A, Maltese M, Madeo G, Martella G, Poli S, Schirinzi T, Bonsi P, Pisani A
Negative allosteric modulation of mGlu5 receptor rescues striatal D2 dopamine receptor dysfunction in rodent models of DYT1 dystonia.
Neuropharmacology. 2014 Oct;85:440-50. Epub 2014 Jun 19 PubMed: 24951854PAPER Arsova A, Møller TC, Vedel L, Hansen JL, Foster SR, Gregory KJ, Bräuner-Osborne H
Detailed In Vitro Pharmacological Characterization of Clinically Tested Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5.
Mol Pharmacol. 2020 Jul;98(1):49-60. Epub 2020 May 1 PubMed: 32358164PAPER Bennett KA, Sergeev E, MacSweeney CP, Bakker G, Cooper AE
Understanding exposure-receptor occupancy relationships for metabotropic glutamate receptor 5 (mGlu5) negative allosteric modulators across a range of pre-clinical and clinical studies.
J Pharmacol Exp Ther. 2021 Feb 4; PubMed: 33541889PAPER Rascol O, Fox S, Gasparini F, Kenney C, Di Paolo T, Gomez-Mancilla B
Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.
Parkinsonism Relat Disord. 2014 Sep;20(9):947-56. Epub 2014 May 14 PubMed: 24951359PAPER Wang WW, Zhang XR, Zhang ZR, Wang XS, Chen J, Chen SY, Xie CL
Effects of mGluR5 Antagonists on Parkinson's Patients With L-Dopa-Induced Dyskinesia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Front Aging Neurosci. 2018;10:262. Epub 2018 Sep 11 PubMed: 30271338Current Filters
- Date Range : Mar 2020 to Mar 2021 x